Myconic Capital is a Canadian investment issuer which pursues seed and Series A level investments in public and private companies. Myconic has a track record of generating return on investment for its shareholders. Management continues to evaluate potential investments which meet the following criteria:
Novel Industries or Mining/Exploration
Well Defined Liquidity Roadmap
Vancouver, British Columbia, June 1, 2021 / Globe Newswire / – Myconic Capital Corp. (NEO: MEDI) is pleased to announce that effective June 3, 2021 it will change its name to KetamineOne Capital Limited (“Ketamine One” or the “Company”) from Myconic Capital Corp. and do business under the “Ketamine One” brand (the “Name Change”).
Vancouver, British Columbia, May 27th, 2021 / Globe Newswire / – Myconic Capital Corp. (NEO: MEDI) (the “Company” or “Myconic”) is pleased to announce that the Company has entered into a definitive share purchase agreement (the “Agreement”), dated May 26, 2021, pursuant to which it will acquire 100% of each class of the issued and outstanding shares of KGK Science Inc. (“KGK”) from Auxly Cannabis Group Inc. (TSX: XLY) (“Auxly”) as an investment (the “Transaction”).
Vancouver, British Columbia, May 18, 2021 / Globe Newswire / – Myconic Capital Corp. (formerly, Auralite Investments Inc.) (CSE: MEDI) (the “Company” or “Myconic”) is pleased to announce that the Company has moved the listing of its common shares (the “Myconic Shares”) to the NEO Exchange (the “NEO”).
Officers & Directors
CEO & Director
CFO & Director